Cargando…

Cetuximab-Coated Thermo-Sensitive Liposomes Loaded with Magnetic Nanoparticles and Doxorubicin for Targeted EGFR-Expressing Breast Cancer Combined Therapy

BACKGROUND: One major limitation of cancer chemotherapy is a failure to specifically target a tumor, potentially leading to side effects such as systemic cytotoxicity. In this case, we have generated a cancer cell-targeting nanoparticle-liposome drug delivery system that can be activated by near-inf...

Descripción completa

Detalles Bibliográficos
Autores principales: Dorjsuren, Buyankhishig, Chaurasiya, Birendra, Ye, Zixuan, Liu, Yanyan, Li, Wei, Wang, Chaoyang, Shi, Di, Evans, Colin E, Webster, Thomas J, Shen, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7591010/
https://www.ncbi.nlm.nih.gov/pubmed/33122906
http://dx.doi.org/10.2147/IJN.S261671
_version_ 1783600907097735168
author Dorjsuren, Buyankhishig
Chaurasiya, Birendra
Ye, Zixuan
Liu, Yanyan
Li, Wei
Wang, Chaoyang
Shi, Di
Evans, Colin E
Webster, Thomas J
Shen, Yan
author_facet Dorjsuren, Buyankhishig
Chaurasiya, Birendra
Ye, Zixuan
Liu, Yanyan
Li, Wei
Wang, Chaoyang
Shi, Di
Evans, Colin E
Webster, Thomas J
Shen, Yan
author_sort Dorjsuren, Buyankhishig
collection PubMed
description BACKGROUND: One major limitation of cancer chemotherapy is a failure to specifically target a tumor, potentially leading to side effects such as systemic cytotoxicity. In this case, we have generated a cancer cell-targeting nanoparticle-liposome drug delivery system that can be activated by near-infrared laser light to enable local photo-thermal therapy and the release of chemotherapeutic agents, which could achieve combined therapeutic efficiency. METHODS: To exploit the magnetic potential of iron oxide, we prepared and characterized citric acid-coated iron oxide magnetic nanoparticles (CMNPs) and encapsulated them into thermo-sensitive liposomes (TSLs). The chemotherapeutic drug, doxorubicin (DOX), was then loaded into the CMNP-TSLs, which were coated with an antibody against the epidermal growth factor receptor (EGFR), cetuximab (CET), to target EGFR-expressing breast cancer cells in vitro and in vivo studies in mouse model. RESULTS: The resulting CET-DOX-CMNP–TSLs were stable with an average diameter of approximately 120 nm. First, the uptake of TSLs into breast cancer cells increased by the addition of the CET coating. Next, the viability of breast cancer cells treated with CET-CMNP-TSLs and CET-DOX-CMNP-TSLs was reduced by the addition of photo-thermal therapy using near-infrared (NIR) laser irradiation. What is more, the viability of breast cancer cells treated with CMNP-TSLs plus NIR was reduced by the addition of DOX to the CMNP-TSLs. Finally, photo-thermal therapy studies on tumor-bearing mice subjected to NIR laser irradiation showed that treatment with CMNP-TSLs or CET-CMNP-TSLs led to an increase in tumor surface temperature to 44.7°C and 48.7°C, respectively, compared with saline-treated mice body temperature ie, 35.2°C. Further, the hemolysis study shows that these nanocarriers are safe for systemic delivery. CONCLUSION: Our studies revealed that a combined therapy of photo-thermal therapy and targeted chemotherapy in thermo-sensitive nano-carriers represents a promising therapeutic strategy against breast cancer.
format Online
Article
Text
id pubmed-7591010
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-75910102020-10-28 Cetuximab-Coated Thermo-Sensitive Liposomes Loaded with Magnetic Nanoparticles and Doxorubicin for Targeted EGFR-Expressing Breast Cancer Combined Therapy Dorjsuren, Buyankhishig Chaurasiya, Birendra Ye, Zixuan Liu, Yanyan Li, Wei Wang, Chaoyang Shi, Di Evans, Colin E Webster, Thomas J Shen, Yan Int J Nanomedicine Original Research BACKGROUND: One major limitation of cancer chemotherapy is a failure to specifically target a tumor, potentially leading to side effects such as systemic cytotoxicity. In this case, we have generated a cancer cell-targeting nanoparticle-liposome drug delivery system that can be activated by near-infrared laser light to enable local photo-thermal therapy and the release of chemotherapeutic agents, which could achieve combined therapeutic efficiency. METHODS: To exploit the magnetic potential of iron oxide, we prepared and characterized citric acid-coated iron oxide magnetic nanoparticles (CMNPs) and encapsulated them into thermo-sensitive liposomes (TSLs). The chemotherapeutic drug, doxorubicin (DOX), was then loaded into the CMNP-TSLs, which were coated with an antibody against the epidermal growth factor receptor (EGFR), cetuximab (CET), to target EGFR-expressing breast cancer cells in vitro and in vivo studies in mouse model. RESULTS: The resulting CET-DOX-CMNP–TSLs were stable with an average diameter of approximately 120 nm. First, the uptake of TSLs into breast cancer cells increased by the addition of the CET coating. Next, the viability of breast cancer cells treated with CET-CMNP-TSLs and CET-DOX-CMNP-TSLs was reduced by the addition of photo-thermal therapy using near-infrared (NIR) laser irradiation. What is more, the viability of breast cancer cells treated with CMNP-TSLs plus NIR was reduced by the addition of DOX to the CMNP-TSLs. Finally, photo-thermal therapy studies on tumor-bearing mice subjected to NIR laser irradiation showed that treatment with CMNP-TSLs or CET-CMNP-TSLs led to an increase in tumor surface temperature to 44.7°C and 48.7°C, respectively, compared with saline-treated mice body temperature ie, 35.2°C. Further, the hemolysis study shows that these nanocarriers are safe for systemic delivery. CONCLUSION: Our studies revealed that a combined therapy of photo-thermal therapy and targeted chemotherapy in thermo-sensitive nano-carriers represents a promising therapeutic strategy against breast cancer. Dove 2020-10-23 /pmc/articles/PMC7591010/ /pubmed/33122906 http://dx.doi.org/10.2147/IJN.S261671 Text en © 2020 Dorjsuren et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Dorjsuren, Buyankhishig
Chaurasiya, Birendra
Ye, Zixuan
Liu, Yanyan
Li, Wei
Wang, Chaoyang
Shi, Di
Evans, Colin E
Webster, Thomas J
Shen, Yan
Cetuximab-Coated Thermo-Sensitive Liposomes Loaded with Magnetic Nanoparticles and Doxorubicin for Targeted EGFR-Expressing Breast Cancer Combined Therapy
title Cetuximab-Coated Thermo-Sensitive Liposomes Loaded with Magnetic Nanoparticles and Doxorubicin for Targeted EGFR-Expressing Breast Cancer Combined Therapy
title_full Cetuximab-Coated Thermo-Sensitive Liposomes Loaded with Magnetic Nanoparticles and Doxorubicin for Targeted EGFR-Expressing Breast Cancer Combined Therapy
title_fullStr Cetuximab-Coated Thermo-Sensitive Liposomes Loaded with Magnetic Nanoparticles and Doxorubicin for Targeted EGFR-Expressing Breast Cancer Combined Therapy
title_full_unstemmed Cetuximab-Coated Thermo-Sensitive Liposomes Loaded with Magnetic Nanoparticles and Doxorubicin for Targeted EGFR-Expressing Breast Cancer Combined Therapy
title_short Cetuximab-Coated Thermo-Sensitive Liposomes Loaded with Magnetic Nanoparticles and Doxorubicin for Targeted EGFR-Expressing Breast Cancer Combined Therapy
title_sort cetuximab-coated thermo-sensitive liposomes loaded with magnetic nanoparticles and doxorubicin for targeted egfr-expressing breast cancer combined therapy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7591010/
https://www.ncbi.nlm.nih.gov/pubmed/33122906
http://dx.doi.org/10.2147/IJN.S261671
work_keys_str_mv AT dorjsurenbuyankhishig cetuximabcoatedthermosensitiveliposomesloadedwithmagneticnanoparticlesanddoxorubicinfortargetedegfrexpressingbreastcancercombinedtherapy
AT chaurasiyabirendra cetuximabcoatedthermosensitiveliposomesloadedwithmagneticnanoparticlesanddoxorubicinfortargetedegfrexpressingbreastcancercombinedtherapy
AT yezixuan cetuximabcoatedthermosensitiveliposomesloadedwithmagneticnanoparticlesanddoxorubicinfortargetedegfrexpressingbreastcancercombinedtherapy
AT liuyanyan cetuximabcoatedthermosensitiveliposomesloadedwithmagneticnanoparticlesanddoxorubicinfortargetedegfrexpressingbreastcancercombinedtherapy
AT liwei cetuximabcoatedthermosensitiveliposomesloadedwithmagneticnanoparticlesanddoxorubicinfortargetedegfrexpressingbreastcancercombinedtherapy
AT wangchaoyang cetuximabcoatedthermosensitiveliposomesloadedwithmagneticnanoparticlesanddoxorubicinfortargetedegfrexpressingbreastcancercombinedtherapy
AT shidi cetuximabcoatedthermosensitiveliposomesloadedwithmagneticnanoparticlesanddoxorubicinfortargetedegfrexpressingbreastcancercombinedtherapy
AT evanscoline cetuximabcoatedthermosensitiveliposomesloadedwithmagneticnanoparticlesanddoxorubicinfortargetedegfrexpressingbreastcancercombinedtherapy
AT websterthomasj cetuximabcoatedthermosensitiveliposomesloadedwithmagneticnanoparticlesanddoxorubicinfortargetedegfrexpressingbreastcancercombinedtherapy
AT shenyan cetuximabcoatedthermosensitiveliposomesloadedwithmagneticnanoparticlesanddoxorubicinfortargetedegfrexpressingbreastcancercombinedtherapy